The DOI matches its Crossref record; 63 of the 67 references it cites were found in a registry or an index; 11 of the 77 sources its claims cite were checked for support.
GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art
Open accessAbstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are highly effective in improving glycaemic control either as monotherapy or in combination with other hypoglycaemic drugs, and have low incidence of side effects, such as hypoglycaemia, nausea and weight gain, thus increasing patients' adherence to therapy. Methods: In this review we report the most recent studies demonstrating the beneficial effects of GLP-1RAs on renal outcomes, and also discuss the direct and indirect mechanisms through which they confer kidney protection. Finally, we discuss the metabolic and anti-inflammatory effects of GLP-1RAs in diabetic patients with COVID-19 disease. Results: GLP-1RAs have a nephroprotective action, which is expressed through both indirect (improvement of blood pressure and glycaemic control, weight loss) and direct (restoration of normal intrarenal haemodynamics, prevention of ischaemic and oxidative damage) effects. They have shown also metabolic and anti-inflammation beneficial effects in patients with COVID-19 disease. Conclusions: GLP-1RAs prevent albuminuria and slow the decline of renal function towards end stage renal disease in patients with diabetic kidney disease. They might be an opportunity to break the typical inflammation processes of COVID-19 disease.
Overview
CoChat Summary
TL;DR
GLP-1 receptor agonists appear nephroprotective in type 2 diabetes and diabetic kidney disease through indirect effects on blood pressure, glycaemic control and weight, plus direct effects on intrarenal haemodynamics and ischaemic/oxidative damage. They reduce albuminuria and slow renal function decline, though evidence for hard renal endpoints is mixed and further trials are needed.
Key findings
- GLP-1RAs reduce albuminuria and slow the decline of renal function toward end-stage renal disease in patients with diabetic kidney disease, via indirect and direct mechanisms.
- In LEADER (9340 patients, mean follow-up 3.8 years), liraglutide lowered nephropathy incidence by 22% versus placebo, mainly through favourable effects on macroalbuminuria, with slower eGFR decline in moderate/severe CKD.
- In SUSTAIN-6 (3297 patients, 2.1 years), semaglutide reduced onset/worsening of nephropathy (3.8% versus 6.1%) and macroalbuminuria by up to 46%, but showed no difference in ESRD or renal death.
- In AWARD-7 (577 patients with CKD G3/G4, 52 weeks), dulaglutide attenuated eGFR decline versus insulin glargine (−1.1, −1.5 and −2.9 mL/min/1.73 m² in the three groups), with no statistically significant UACR difference.
Methods
- Narrative review of recent studies on GLP-1RA pharmacokinetics/pharmacodynamics, direct and indirect nephroprotective mechanisms, renal outcomes in diabetic patients, and metabolic/anti-inflammatory effects in COVID-19.
- Summarizes randomized controlled trials including LEADER, SCALE, LIRA-RENAL, SUSTAIN, ELIXA, EXSCEL, AWARD-7 and REWIND, plus meta-analyses and guidelines; Table 1 lists renal endpoints and results.
- No systematic review methods, primary data collection, or formal risk-of-bias assessment are described.
Limitations
- The paper states that mechanisms of nephroprotection are poorly understood, clinical use remains limited, high cost is an important limitation for first-line use, and further studies are needed to expand knowledge and long-term cardiovascular/renal outcomes.
- The paper notes that LIRA-RENAL’s neutral result could be partly due to its small sample size and short observation period.
- Evident from the text: this is a narrative review relying on selected trials and post-hoc/exploratory analyses, and the FLOW trial results were still pending, expected in 2024.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
6 Valid · 3 Not valid · 45 Not checked · 34 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Emerging data support the efficacy of GLP-1RAs, in reducing the incidence of major adverse cardiovascular events (MACEs), preventing the onset of macroalbuminuria and slowing the progression of renal damage toward ESRD [5, 6]”
§ GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art > INTRODUCTION
What the sources say
- Partly supportedcites [5] Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Results report less new or worsening nephropathy with semaglutide than with placebo, and the Other Outcomes definition includes a need for continuous renal-replacement therapy. The Discussion says the lower nephropathy risk reflected differences in macroalbuminuria. The paper therefore supports a renal benefit for semaglutide in the studied patients, but does not establish that GLP-1 receptor agonists as a class slow progression to end-stage renal disease. (LLM, conf=0.86)
- Partly supportedcites [6] Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Results (Microvascular Outcomes; page not provided) report fewer nephropathy events with liraglutide than with placebo. The Discussion says this benefit was driven particularly by fewer cases of new-onset persistent macroalbuminuria. Although the Methods include renal-replacement therapy in the nephropathy outcome, the cited results do not establish slower progression to end-stage renal disease; the trial also tested liraglutide, not GLP-1 receptor agonists as a class. (LLM, conf=0.86)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Emerging data support the efficacy of GLP-1RAs, in reducing the incidence of major adverse cardiovascular events (MACEs), preventing the onset of macroalbuminuria and slowing the progression of renal damage toward ESRD [5, 6]”
§ GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art > INTRODUCTION
What the sources say
- Partly supportedcites [5] Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (p. 'Discussion') states that 'Semaglutide-treated patients had a lower risk of new or worsening nephropathy, according to differences in macroalbuminuria,' and the Results ('A Primary Outcome' section) give new or worsening nephropathy in 3.8% vs 6.1% (HR 0.64; 95% CI 0.46–0.88; P=0.005), so the macroalbuminuria-driven renal benefit is supported — but only for semaglutide in this one trial. The claim generalises to the whole GLP-1-receptor-agonist class, which this source does not establish (our copy invokes the class only for pulse rate and safety profile, not for renal outcomes), and the reported endpoint is a composite that also includes persistent doubling of serum creatinine or need for renal-replacement therapy (Table 2 footnote, 'Other Outcomes'), not macroalbuminuria onset alone. (LLM, conf=0.75)
- Partly supportedcites [6] Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
Our copy of LEADER supports the macroalbuminuria component for liraglutide specifically: the Discussion states 'The benefit with liraglutide was driven by lower rates of renal outcomes, such as new-onset persistent macro-albuminuria in particular,' and the Results (Microvascular Outcomes) report a lower nephropathy event rate with liraglutide (1.5 vs. 1.9 per 100 patient-years; HR 0.78, 95% CI 0.67–0.92, P=0.003) in adults with type 2 diabetes at high cardiovascular risk. What the source does not support is the class-level framing 'GLP-1 receptor agonists' — this is a single-agent (liraglutide) trial in one defined high-risk population, and the paper itself hedges the mechanism ('It is uncertain whether this finding relates to the direct effects of liraglutide on kidney function'), while noting that another GLP-1 RA, lixisenatide, showed no cardiovascular benefit in ELIXA. The citing sentence also bundles reduction in MACE and slowing of progression toward ESRD; only the former is firmly established in this paper, since the nephropathy composite (which included renal-replacement therapy and death from renal disease, per Methods/Outcomes) was driven chiefly by new-onset macroalbuminuria rather than by end-stage endpoints. (LLM, conf=0.78)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide reduces the incidence of de novo macroalbuminuria. Nevertheless, no difference was found regarding the incidence of ESRD and death for renal causes.”
§ GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art > GLP-1RAs and renal outcomes in diabetic patients: review of randomized controlled trials
What the sources say
- Supportedcites [5] Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med source
The Discussion (page not provided) says semaglutide-treated patients had a lower risk of new or worsening nephropathy than placebo recipients, driven by differences in macroalbuminuria. The trial results also report fewer new or worsening nephropathy events with semaglutide. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“exenatide did not produce any significant improvement in eGFR decline and incidence of ESRD and renal-related death in the EXSCEL trial”
§ GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art > GLP-1RAs and renal outcomes in diabetic patients: review of randomized controlled trials
What the sources say
- Could not verifycites [57] Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Methods (Outcomes) list cardiovascular endpoints but do not report results for eGFR decline, ESRD, or renal-related death. The Methods (Randomization and Trial Regimen) mention eGFR only as a threshold for stopping treatment. Searches for renal outcomes and those specific endpoints found no passage establishing whether exenatide significantly improved them. (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“there were no statistically significant differences on the reduction of UACR.”
§ GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art > GLP-1RAs and renal outcomes in diabetic patients: review of randomized controlled trials
What the sources say
- Could not verifycites [59] Tuttle, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
Our copy is of the EXSCEL trial (once-weekly exenatide vs placebo) and contains no passage on AWARD-7, dulaglutide versus insulin glargine, or urinary albumin-to-creatinine ratio; searches for 'UACR/albumin-to-creatinine', 'albuminuria/nephropathy/renal', and 'dulaglutide/AWARD-7' returned only exenatide-placebo methods and results (Methods: Randomization and Trial Regimen, Outcomes, Statistical Analysis; Results: Changes in Risk Factors, Additional Efficacy Outcomes). The renal-related content present concerns eGFR-based eligibility/discontinuation criteria, not albuminuria endpoints (Methods, Trial Population). Since our copy neither states nor contradicts the attributed AWARD-7 finding, and it does not credit that finding to any named work, the claim cannot be verified against this source. (LLM, conf=0.70)
plainn = 577- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
50 more claims · 1 with their cited sources checked
Create a free account to see all 88 claims and to verify the 66 references still open.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, these newer therapeutic agents may decrease cardiovascular disease (CVD) 20 and diabetic kidney disease (DKD), 21 the major life-shortening complications of diabetes.[22][23][24]”
From Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, based on data from the SUSTAIN-6 and SELECT trials showing reduced CVD in people with T2D and in OW/OB people without diabetes, 20,40 it is likely that patients with T1D would benefit from use of these novel agents not only for weight loss and improved glycemic control but also due to anticipated reductions in CVD and DKD.”
From Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes (2025) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art > GLP-1RAs and renal outcomes in diabetic patients: review of randomized controlled trials
“the semaglutide arm performed better than placebo for MACEs (6.6% versus 8.9%), glycaemic control”
§ GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art > GLP-1RAs and renal outcomes in diabetic patients: review of randomized controlled trials
“(mean HbA1c −1.1% versus −1.4%), weight loss (−3.6 vs -4.9 kg)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art > GLP-1RAs and renal outcomes in diabetic patients: review of randomized controlled trials
“The AWARD-7 study [59] recruited and randomized 577 diabetic patients with CKD stages G3 and G4 in three arms: (i) dulaglutide, 1.5 mg weekly; (ii) dulaglutide, 0.75 mg weekly; and (iii) insulin glargine, all in combination with insulin lispro.”
§ GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art > References
“59. Tuttle KR, Lakshmanan MC, Rayner B et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228– 1239 28910237 10.1056/NEJMoa1612917 PMC9792409”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art > GLP-1RAs and renal outcomes in diabetic patients: review of randomized controlled trials
“This randomized controlled trial is the only one with a superiority study design.”
§ GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art > GLP-1RAs and renal outcomes in diabetic patients: review of randomized controlled trials
“The primary composite endpoint, assessed for non-inferiority and superiority, included the incidence of MACEs.”
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 4×
“In particular, the SUSTAIN-6 trial [5] was designed to demonstrate the noninferiority of semaglutide compared with placebo in terms of cardiovascular safety on a sample of 3297 patients.”
BackgroundInfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“In experimental models of diabetes, GLP-1 has been shown to inhibit apoptosis of β cells and promote their proliferation through the recruitment of cellular precursors, thus implementing the availability of functionally active β cells [7, 8].”
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 3×
“ELIXA [55] was a randomized, double-blind, parallel-group study designed to evaluate the impact of lixisenatide on cardiovascular risk compared with placebo in a population of 6068 diabetic adults with a recent episode of acute coronary syndrome.”
InfluentialMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“In experimental models of diabetes, GLP-1 has been shown to inhibit apoptosis of β cells and promote their proliferation through the recruitment of cellular precursors, thus implementing the availability of functionally active β cells [7, 8].”
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Research works printed but not linked: 1
- Tuttle, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 377, 1228, 10.1056/nejmoa1612917 · DOI · Paper page
Cited by
Patel, R. P., Wadid, M., Makwana, B., Kumar, A., Khadke, S., Bhatti, A. W., Banker, A., Husami, Z., Labib, S. B., Venesy, D. M., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.07.006 · Cited by 90
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Hong, C.-T., Chen, J.-H., & Hu, C.-J. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01090-x · Cited by 78
Lonardo, A., Mantovani, A., Targher, G., & Baffy, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113320 · Cited by 85
Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities
Patera, F., Gatticchi, L., Cellini, B., Chiasserini, D., & Reboldi, G. (2024) · Biomolecules · doi:10.3390/biom14010137 · Cited by 75
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56
Metadata
- Authors
- Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S.
- Affiliations
- Ospedale Cannizzaro (IT)
- University of Catania (IT)
- University of Bari Aldo Moro (IT)
- University of Palermo (IT)
- Corresponding author
- Maccarrone, Rosario
- ORCID
- Venue
- Clinical Kidney Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-03-12
- Volume
- 15
- Issue
- 9
- Pages
- 1657-1665
- ISSN
- 2048-8505 (ISSN-L)
- 2048-8513
- PMC
- PMC9394722
- OpenAlex
- W4214865414
- Cited by
- 54
- References
- 67
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 21 · 2023: 5 · 2022: 2
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Kidney Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- IRIS UniPA (University of Palermo) (submittedVersion, other-oa)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- GLP-1 receptor agonists, diabetic nephropathy, type 2 diabetes, renal protection, albuminuria, end-stage renal disease, renal function decline, oxidative stress, COVID-19 pandemic, anti-inflammatory activity, glycemic control, weight loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. https://app.cochat.ai/papers/10.1093/ckj/sfac069
- The paper
- Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022). GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfac069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Figure 1: Physiologic effects of GLP-1 (adapted from Granata et al. [11]).](https://figures.cochat.ai/paper-figures/f5985ea9fd764c6294982720a40f6dfd/glp-1-receptor-agonists-and-renal-outcomes-in-patients-with-diabetes-mellitus-figure-1.jpg)
![Figure 2: Direct and indirect effects through which GLP-1RAs confer nephroprotection (adapted from Granata et al. [11]).](https://figures.cochat.ai/paper-figures/46814820a0d543ff9ea0950856ca1960/glp-1-receptor-agonists-and-renal-outcomes-in-patients-with-diabetes-mellitus-figure-2.jpg)